News

Upcoming Third Quarter Financial Results from BioCryst

Upcoming Third Quarter Financial Results from BioCryst

BioCryst Pharmaceuticals to Announce Financial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is set to report its financial results for the third quarter of 2024. The anticipated announcement is scheduled for November 4, marking an important date for the company and its stakeholders alike.

Conference Call Scheduled

On the same day as the results release, BioCryst management will conduct a conference call and webcast at 8:30 a.m. ET. This session is designed to discuss the financial outcomes and offer a comprehensive update on the company's corporate developments.

How to Access the Conference Call

Investors and interested parties can join the live call by dialing either 1-844-481-2942 for callers within the United States or 1-412-317-1866 for international participants. Additionally, a live webcast alongside a replay will be accessible in the investor section of BioCryst's official website.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, a dedicated biotechnology firm, focuses on enhancing the well-being of individuals facing complement-mediated and other rare diseases. With a strong foundation in structure-guided drug design, the company aims to develop innovative oral small-molecule and protein therapeutics targeting challenging diseases.

Key Product Offerings

One of BioCryst's notable products is ORLADEYO (berotralstat), recognized as the first oral, once-daily plasma kallikrein inhibitor. The company is actively working on a pipeline consisting of both small-molecule and protein therapies that address various medical needs.

Looking Ahead

As BioCryst Pharmaceuticals moves closer to releasing their financial results, stakeholders are keen to learn about the company’s progress, ongoing research initiatives, and their strategic plans for growth. The upcoming conference call is expected to provide valuable insights into their financial health and operational strategies.

Connecting with BioCryst

For updates and detailed information, interested individuals are encouraged to explore BioCryst’s website or follow the company on LinkedIn. Maintaining an active communication line with investors and healthcare professionals is a priority for BioCryst as it seeks to forge ahead in the biotechnology sector.

Frequently Asked Questions

When will BioCryst report its third quarter financial results?

BioCryst Pharmaceuticals will release its third quarter 2024 financial results on November 4.

What time is the conference call scheduled for?

The conference call is set for 8:30 a.m. ET on the same day as the financial results announcement.

How can I access the conference call?

To access the call, dial 1-844-481-2942 for domestic callers or 1-412-317-1866 for international callers. A webcast will also be available.

What is ORLADEYO?

ORLADEYO (berotralstat) is BioCryst’s first oral plasma kallikrein inhibitor available for once-daily administration.

How can I get in touch with BioCryst?

For inquiries, you can contact John Bluth at +1 919 859 7910 or via email.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

US Foods Faces Major Strike Threat Over Driver Contracts

Updated Category News Views 84

Teamsters Prep for Possible Strike Against US Foods You can almost hear the union drums beating as 260 drivers from Teamsters Local 282 in New York gear up for what could be a major confrontation with US Foods. The message is loud and clear: pay us what we're worth, or watch your delivery chain grind to a halt. With unanimous approval to strike, this isn't just a...

Continue Reading
PMET Grows Mineral Assets at Shaakichiuwaanaan

Updated Category News Views 100

Resource Expansion at the Shaakichiuwaanaan Property You ever see a resource report that makes you do a double take? That's the vibe here with PMET's game-changing update on their Shaakichiuwaanaan property in Quebec. They've crunched the numbers at the Helios Caesium Zone and CV4 Pegmatite, and the results? A juicy increase in the grade, scale, and tonnage across three...

Continue Reading
GNSS Simulator Market: $425M by 2031, Key Insight

Updated Category News Views 118

GNSS Simulator Market: Gadgets Meet Growth A market that's been quietly bubbling away on the back burner is about to boil over: The GNSS Simulator Market, pegged at a neat $424.6 million by 2031. Yeah, it might be niche, but those in the know can't get enough of these satellite-signal replicators. Why GNSS Simulators are Crushing It There's a bunch of reasons why GNSS...

Continue Reading
EAF Relief Fund Launches After Learjet Disaster

Updated Category News Views 103

Mobilizing Aid: A Community in Crisis Not every day you wake up to a story that digs into your gut like this one. The folks at the Green Acres Mobile Home Community in Palm Beach County got dealt a raw deal. A Learjet crash shook their world apart on November 1st, leaving nine lives lost on that flight and sending hundreds of residents scrambling from their homes. It's a...

Continue Reading
RSPO RT2026 Tackles Indonesian Fires and Export Shifts

Updated Category News Views 15

Indonesia's Burning Questions There's been a lot of smoke—literally and figuratively—hanging over the palm oil industry in Indonesia this year. At the RSPO's Annual Roundtable on Sustainable Palm Oil (RT2026), attendees didn't shy away from addressing the harsh realities. In a year marked by rampant fires, thanks to the blistering El Niño, the RSPO showcased data...

Continue Reading
Staypineapple Backs Vets: A Heartwarming Initiative

Updated Category News Views 151

When Hotels Stand Up for Heroes Every now and then, you stumble upon a company doing something genuinely good, and Staypineapple's effort this November is one of those rare gems. In honor of Veterans Day, they're opening their checkbook to sling some real support to our nation’s vets and retired first responders. Their chosen cause? The American Humane Society's...

Continue Reading
HashKey and AMBR Unite to Push AI Frontiers in Finance

Updated Category News Views 34

Shaping the Future with AI Integration In the whirlwind of innovation, there's always the ones braving the frontier, pushing the very boundaries of what we deem possible. Today, it's HashKey Capital and AMBR joining forces, marching into uncharted financial territories. This partnership is more than just a signature on a piece of paper; it's a declaration—a commitment...

Continue Reading
Verismo's SynKIR-110: Revolutionizing CAR T Therapy?

Updated Category News Views 73

Clinical Stage Wonders and Bold Claims Here's the lowdown on the latest tale from Verismo Therapeutics, a name that's trying real hard to distinguish itself in the CAR T therapy arena. Grab a coffee, pal, and let's wade through what's cooking at their camp with the SynKIR™-110. Breaking Down the Science Jargon For you folks not knee-deep in immunotherapy, let me spell...

Continue Reading
Silvercorp Updates El Domo Budget Amid Challenges

Updated Category News Views 78

Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...

Continue Reading
BD Appoints Bagnato as Peripheral Intervention Head

Updated Category News Views 13

A New Captain for BD's Peripheral Ship Time to pay attention, folks. Franklin Lakes just sent an interesting ripple through their workforce headlines, announcing Bridget Bagnato taking the reins as Worldwide President of BD's Peripheral Intervention division. Come November 16, this medical tech veteran, who's clocked over 27 years with BD, is set to start steering their...

Continue Reading

Top 5 Most Recently Viewed Articles

SEATOM Selected for NATO's Accelerator Programme Growth

Updated Category News Views 161

SEATOM's Selection for NATO's Accelerator Programme Today, SEATOM announced a significant milestone as it was chosen to participate in the NATO Defence Innovation Accelerator for the North Atlantic (DIANA) 2026 Challenge Programme. This prestigious selection underscores SEATOM's innovative approach to developing nuclear technology tailored for maritime and extreme...

Continue Reading
OpenAI's New Device Development Following $6.5 Billion Acquisition

Updated Category News Views 194

OpenAI Completes a Major Acquisition OpenAI has recently wrapped up a remarkable deal by acquiring Jony Ive's AI hardware startup, io Products, for a staggering $6.5 billion. This acquisition brings the design genius, renowned for his work at a major tech giant, into OpenAI's fold to help create a new generation of smart devices. Key Developments Post-Acquisition The...

Continue Reading
Opportunities for KinderCare Investors Amid Class Action News

Updated Category News Views 151

Opportunities for KinderCare Investors Robbins Geller Rudman & Dowd LLP has announced a significant opportunity for investors of KinderCare Learning Companies, Inc. (NYSE: KLC) who have experienced substantial losses. This is a pivotal moment for shareholders as they can now seek to lead a class action lawsuit against the company. Understanding the Class Action Lawsuit...

Continue Reading
Baltic Horizon Fund Sees Positive NAV Growth in May 2025

Updated Category News Views 128

Growth of Baltic Horizon Fund's NAV in May 2025 The Baltic Horizon Fund reported an increase in its net asset value (NAV) per unit, which rose to EUR 0.6757 at the close of May 2025. This figure represents a slight gain from the NAV of EUR 0.6740 recorded at the end of April 2025. The fund's overall net asset value reached EUR 97.0 million, up from EUR 96.8 million in the...

Continue Reading
Autolus Therapeutics Highlights CARLYSLE Trial Findings at ASH 2025

Updated Category News Views 239

Autolus Therapeutics Showcases CARLYSLE Trial Results Autolus Therapeutics plc (Nasdaq: AUTL), a biopharmaceutical leader in developing innovative T cell therapies, recently showcased promising preliminary data from the CARLYSLE trial, which focuses on severe refractory systemic lupus erythematosus (srSLE). The data were presented during a special session at a leading...

Continue Reading